Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
J Am Heart Assoc. 2024 Feb 20;13(4):e029042. doi: 10.1161/JAHA.123.029042. Epub 2024 Feb 16.
J Am Heart Assoc. 2024.
PMID: 38362909
Free PMC article.
Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
Tsutsui H, Sakamaki H, Momomura SI, Sakata Y, Kotobuki Y, Linden S, Reifsnider OS, Rakonczai P, Stargardter M, Murata T, Hirase T, Nitta D.
Tsutsui H, et al. Among authors: stargardter m.
J Cardiol. 2023 Jun;81(6):522-530. doi: 10.1016/j.jjcc.2023.02.007. Epub 2023 Feb 28.
J Cardiol. 2023.
PMID: 36858174
Free article.
Item in Clipboard
Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping.
Yang M, Vioix H, Sachdev R, Stargardter M, Tosh J, Pfeiffer BM, Paik PK.
Yang M, et al. Among authors: stargardter m.
Value Health. 2023 Apr;26(4):487-497. doi: 10.1016/j.jval.2022.11.018. Epub 2022 Dec 8.
Value Health. 2023.
PMID: 36503033
Free PMC article.
Item in Clipboard
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Tafazzoli A, Reifsnider OS, Bellanca L, Ishak J, Carrasco M, Rakonczai P, Stargardter M, Linden S.
Tafazzoli A, et al. Among authors: stargardter m.
Eur J Health Econ. 2023 Dec;24(9):1441-1454. doi: 10.1007/s10198-022-01555-6. Epub 2022 Dec 4.
Eur J Health Econ. 2023.
PMID: 36463524
Free PMC article.
Item in Clipboard
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A.
Reifsnider OS, et al. Among authors: stargardter m.
Am J Kidney Dis. 2022 Jun;79(6):796-806. doi: 10.1053/j.ajkd.2021.09.014. Epub 2021 Nov 6.
Am J Kidney Dis. 2022.
PMID: 34752913
Free article.
Clinical Trial.
Item in Clipboard
Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States.
Stargardter M, McBride A, Tosh J, Sachdev R, Yang M, Ambavane A, Mittal M, Vioix H, Liu FX.
Stargardter M, et al.
J Med Econ. 2021 Jan-Dec;24(1):816-827. doi: 10.1080/13696998.2021.1942017.
J Med Econ. 2021.
PMID: 34126842
Free article.
Item in Clipboard
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider OS, Kansal AR, Franke J, Lee J, George JT, Brueckmann M, Kaspers S, Brand SB, Ustyugova A, Linden S, Stargardter M, Hau N.
Reifsnider OS, et al. Among authors: stargardter m.
ESC Heart Fail. 2020 Dec;7(6):3910-3918. doi: 10.1002/ehf2.12985. Epub 2020 Sep 10.
ESC Heart Fail. 2020.
PMID: 32909680
Free PMC article.
Item in Clipboard
Cite
Cite